Market reactionShares rose 13% on Nov 3.
Chemomab develops nebokitug, an antibody against CCL24, and plans to merge with Scipher Medicine to test it in rheumatoid arthritis; nebokitug is not approved.
Nebokitug’s PSC Phase 2 showed safety and biomarker improvements; a Phase 3 partner is still sought. Chemomab’s future depends on its proposed Scipher merger and $30 million private placement at closing, now expected in early 2027. The combined company plans PrismRA-guided rheumatoid arthritis development, starting in the first half of 2027 with results in 2028. Chemomab reported $6.7 million cash at June 30, 2026 and expects existing liquidity to fund operations through the first quarter of 2027, leaving limited room for closing delays.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Scipher merger closes
Will shareholders approve the merger and will closing deliver the planned financing within Chemomab’s projected liquidity window?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Scipher closing shifts to early 2027, narrowing Chemomab’s financing cushion
Chemomab merging into Scipher Medicine to pivot nebokitug into AI-selected RA, abandoning PSC after Phase 2 biomarker-only results
Nebokitug's Phase 3 path in PSC is defined; whether Chemomab can fund it before Q1 2027 runway expires is the central question
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Liver and digestive diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
11 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.